ストックスクリーナーアプリを入手
133.69
0.03%
-0.04
アフターアワーズ：
134.22
0.53
+0.40%
前日終値:
$133.73
開ける：
$133.83
24時間の取引高:
5.02M
Relative Volume:
0.84
時価総額：
$165.99B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
18.19
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+4.65%
6か月 パフォーマンス:
+4.85%
1年 パフォーマンス:
+22.55%
1日の値動き範囲:
$132.59
$136.19
1週間の範囲:
$129.42
$136.32
52週間の値動き範囲:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
133.69 | 166.04B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,082.92 | 949.47B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
231.29 | 554.09B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.40 | 376.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.24 | 295.69B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.12 | 287.74B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
GILD: Promising Results for Livdelzi in Treating Primary Biliary Cholangitis - GuruFocus
Gilead liver drug Livdelzi normalizes key PBC marker in 2‑year study - Stock Titan
Flputnam Investment Management Co. Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
User - The Chronicle-Journal
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) - Business Wire
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
Gilead Sciences Secures First FDA Approval For Hepcludex In Chronic Hepatitis Delta Virus Treatment - BioPharma APAC
Eukles Asset Management Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Allstate Corp Buys 47,838 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio - Insider Monkey
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy - TradingView
Todd Asset Management LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Legal & General Group Plc Has $1.27 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Simplify Asset Management Inc. Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Life Cycle Investment Partners Ltd Takes $1.42 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Genus Capital Management Inc. Has $16.69 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead donates 400,000 doses of AmBisome and $9.2 mln to combat deadly visceral leishmaniasis - Новости GxP
Zacks Research Expects Lower Earnings for Gilead Sciences - MarketBeat
[Press release] FDA grants accelerated approval to Gilead’s Hepcludex® (bulevirtide-gmod), the first and only approved treatment for chronic hepatitis delta virus (HDV) - European AIDS Treatment Group
Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’ - Insider Monkey
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference - MarketBeat
Axxcess Wealth Management LLC Has $4.44 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gilead Sciences leans on HIV growth as deals build oncology, inflammation pipeline - MSN
LSV Asset Management Has $508.91 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Global Retirement Partners LLC Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains - Yahoo Finance
Gilead Sciences Inc. (NASDAQ: GILD) Holds Steady as HIV and Oncology Portfolio Drives Income - foreignpolicyjournal.com
Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh Trade Ideas — BMFBOVESPA:GILD34 - TradingView
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement - TradingKey
Gilead wins FDA approval for first hepatitis delta treatment By Investing.com - Investing.com Nigeria
Gilead's drug wins first-ever US approval for deadly liver infection - Reuters
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment - Yahoo Finance
Gilead Sciences Gets FDA Green Light for Chronic HDV Drug - Moomoo
US FDA approves Gilead's drug for deadly liver infection - Yahoo
Gilead Sciences stock rises after FDA approves HDV treatment - Investing.com
New Gilead shot is first FDA-approved treatment for deadly hepatitis D - Stock Titan
Gilead Sciences stock rises after FDA approves HDV treatment By Investing.com - Investing.com Canada
(bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) - Business Wire
GILD: Gilead's Trodelvy Gains Positive Opinion for TNBC Treatmen - GuruFocus
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $180 - Moomoo
Gilead Wins CHMP Positive Opinion for Breast Cancer Drug Trodelvy - Moomoo
GILD Receives Positive EMA Opinion for Trodelvy in Breast Cancer Treatment - GuruFocus
Gilead’s Trodelvy receives EU committee backing for breast cancer By Investing.com - Investing.com Australia
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer - BioSpace
Gilead’s Trodelvy receives EU committee backing for breast cancer - Investing.com
in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors - Business Wire
Keudell Morrison Wealth Management Purchases Shares of 16,022 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences acquires Tubulis for $5bn - Yahoo Finance
Gilead Sciences completes Tubulis acquisition for $5bn - Pharmaceutical Technology
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.04%
0.82%
大文字化:
|
ボリューム (24 時間):